Is JCR Pharmaceuticals Co., Ltd. (JCRRF) a Buy, Sell, or Hold?
OTC : JCRRF
JCR Pharmaceuticals Co., Ltd.
$3.31 USD
$0 (0.0%)
- Volume
- 476
- Average Volume
- 23
- Market Capitalization
- $403.8M
- P/E Ratio
- 28.60
- Dividend Yield
- 3.91%
- Price Target
- Year High
- $5.00
- Year Low
- $3.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.16
| Source | Headline |
|---|---|
|
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo® businesswire.com - 2026-06-17 12:30:00 |
|
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
HYOGO, Japan--(BUSINESS WIRE)--JCR presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, held June 4-7, 2026. businesswire.com - 2026-06-08 13:34:00 |
|
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it will present new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases. businesswire.com - 2026-05-28 11:43:00 |
|
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
HYOGO, Japan--(BUSINESS WIRE)--JCR announced today that it presented preclinical data from its novel platform technologies in oral and poster sessions at the ASGCT Annual Meeting. businesswire.com - 2026-05-18 12:58:00 |
|
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
HYOGO, Japan--(BUSINESS WIRE)--JCR will present preclinical data from its novel platform technologies, including JUST-AAV gene therapy, at the ASGCT 29th Annual Meeting this week. businesswire.com - 2026-05-11 13:06:00 |
